- Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesityWith PolyPeptide manufacturing peptides such as GLP-1 medicines, Samsung Biologics has identified the deal as a way to tap into fast-growing demand for obesity drug production services.BioSpace · 3d ago↗ source
- Biotech industry leaders file brief backing FDA against ‘malicious’ mifepristone challengeA group of 61 biopharma companies, executives and investors has filed an amicus brief in support of the FDA in an ongoing case brought by Louisiana meant to remove access to the abortion pill mifep…Fierce Biotech · 3d ago↗ source
- Agios axes next-gen sickle cell candidate after it fails to best Novo’s assetAgios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the…